GlassScriptPhysician profile
Phillip R Northcross
NPI 1831166677
$39,185.53
in general payments reported to CMS, 2019-2025
29 companies · $5,934 in 2025
The $5,934 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,483 · 2020: $1,486 · 2021: $2,031 · 2022: $1,939 · 2023: $6,194 · 2024: $12K · 2025: $5,934.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $7,496 · Travel and Lodging: $1,131 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,600.00 |
| Food and Beverage | $7,496.14 |
| Travel and Lodging | $1,130.80 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $21,493.95 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $6,611.68 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $1,555.38 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,509.95 | 2019-2025 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $1,271.90 | 2021-2025 | Nexletol, Nexlizet |
| Sanofi-Aventis U.S. LLC | $1,217.60 | 2019-2023 | |
| Kowa Pharmaceuticals America, INC. | $686.94 | 2020-2024 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $684.62 | 2019-2023 | Steglatro, Steglujan, Belsomra |
| Glaxosmithkline, LLC. | $589.42 | 2019-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $509.23 | 2021-2025 | |
| Abbott Laboratories | $507.57 | 2019-2025 | Diamondback Peripheral |
| Amgen INC. | $357.62 | 2019-2025 | Repatha, Otezla, Otezla |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $354.06 | 2020-2023 | Lifevest |
| Novo Nordisk INC | $267.24 | 2020-2025 | |
| Mannkind Corporation | $246.35 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $220.82 | 2019 | |
| Shield Therapeutics INC | $157.94 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $137.05 | 2019-2021 | |
| Madrigal Pharmaceuticals | $131.37 | 2025 | Rezdiffra |
| Amarin Pharma, INC. | $112.48 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $91.31 | 2025 | Rexulti |
| Medtronic Vascular, INC. | $88.95 | 2019 | |
| Arbor Pharmaceuticals, INC. | $85.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.58 | 2019-2021 | |
| Medtronic, INC. | $69.56 | 2023 | Venaseal |
| Nalpropion Pharmaceuticals LLC | $67.08 | 2019 | |
| Antares Pharma, INC. | $46.38 | 2021 | |
| Abbvie INC. | $21.42 | 2023 | |
| Allergan, INC. | $12.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Northcross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.